Trade off: Ischemic/Thrombotic vs Bleeding
Renato D. Lopes, MD, MHS, PhD
Don't Miss It! Rapid & Accurate AAV Diagnosis
Silke R. Brix, MD, MRCP, SCPR
Andreas Kronbichler, MD
Optimizing AAV Outcomes: Maintenance Therapies
Bernhard Hellmich, MD
Implementing the SOC Induction Therapies in AAV
Decoding ANCA-Associated Vasculitis (AAV): From Suspicion to Solution
Elevating Care for Patients With Severe Renal Disease in AAV
Tailoring Treatment for Optimal Outcomes in Patients With AAV
Patient Case Study: Obesity and VTE
Alexander T. Cohen, MD, MBBS
How Do We Translate Real-World VTE Data Into Everyday Clinical Practice for Ongoing Anticoagulation?
Patient Case Study: Obesity
Valeria Caso, MD, PhD
Implications Associated With Integrating Both Real-World Data and Clinical Trial Data Into Clinical Practice: VTE Considerations
AHA 2024 and Acoramidis: Impact on the Future of ATTR-CM Patient Care
Mazen Hanna, MD
LDL-C Management Trends in ASCVD Patients
Keith C. Ferdinand, MD, FACC, FAHA , FASPC, FNLA, FPCNA
Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)
John Russell, MD
Noel Dasgupta, MD, FACC
Sami Khella, MD
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Stephen Nicholls, FRACP, FACC, FESC, FAHA
Tirzepatide reduces HF events in patients with HFpEF and obesity
Milton Packer, MD
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Cardiology Academy… but how about a more personalized experience?
Press cancel to remain on Global Cardiology Academy. Press the link below or the continue button to keep going.